Isis' CEO Hosts To Review KYNAMRO Data Presented At The ESC 2012 Meeting Conference (Transcript)

Isis Pharmaceuticals, Inc. (ISIS)

Review KYNAMRO Data Presented at the ESC 2012 Meeting Conference Transcript

August 29, 2012 10:00 AM ET

Executives

Dr. Stanley Crooke - Chairman and CEO

Dr. Klaus Parhofer - Professor, Metabolism and Endocrinology, Ludwig-Maximilians University, Munich

Lynne Parshall - Chief Operating Officer

Rich Geary - Senior Vice President, Development

Walter Singleton - Vice President, Development and CMO

Wade Walke - Executive Director, Corporate Communications and IR

Analysts

Nicholas Bishop - Cowen & Company

Stephen Willey - Stifel Nicolaus

Carol Werther - Summer Street

Chad Messer - Needham & Company

Sam Colin - First Manhattan Company

Presentation

Operator

Good day, ladies and gentlemen. And welcome to Isis Pharmaceuticals' Conference Call to Review KYNAMRO Data that was recently presented at the ESC 2012 Meeting. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the conference over to Dr. Stanley Crooke, Chairman and CEO. Please proceed.

Dr. Stanley Crooke

Good morning, everyone. And thanks for joining us today. As [Donato] indicated the purpose of this call is to have Dr. Parhofer to review the additional results or some additional results on KYNAMRO that were presented at the European Society of Cardiology Meeting this morning in Munich.

Joining us on today’s call are Dr. Klaus Parhofer, Professor of Metabolism and Endocrinology at Ludwig-Maximilians University in Munich; Lynne Parshall, Chief Operating Officer; Rich Geary, Senior Vice President of Development; Walter Singleton, Vice President, Development and Chief Medical Officer; and Wade Walke, Executive Director, Corporate Communications and Investor Relations.

If you liked this article you might like

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Isis Pharmaceuticals Changes Its Name

Isis Pharmaceuticals Changes Its Name

Highlighted Post-Market Laggard: ISIS Pharmaceuticals (ISIS)

Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity

ISIS Pharmaceuticals (ISIS) Weak On High Volume